You are here

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Tucson, Arizona, 85715 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atrophic Vaginitis, Atrophy, Vaginitis
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
45-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Generally healthy postmenopausal women with symptoms of atrophic vaginitis including
vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse.

The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Women who do not have a clinical diagnosis of atrophic vaginitis.

NCT00137371
Pfizer
Completed
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Atrophic Vaginitis
NCT00167921
Females
45+
Years
Multiple Sites
Atrophic Vaginitis, Atrophy, Vaginitis
NCT00137371
Females
45+
Years
Multiple Sites
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis
This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Atrophic Vaginitis
  • Atrophy
  • Vaginitis
  • Drug: PVC (daily for 21 days, 7 days off)
  • Drug: PVC (twice weekly)
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
480
September 2007
Not Provided

Inclusion Criteria:

Generally healthy postmenopausal women with symptoms of atrophic vaginitis including vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse.

The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.

Exclusion Criteria:

Women who do not have a clinical diagnosis of atrophic vaginitis.

Sexes Eligible for Study: Female
45 Years to 80 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT00137371
0713S5-413
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Principal Investigator: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now